Waters Parkerson & Co’s DexCom DXCM Stock Holding History

Waters Parkerson & Co’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-354,452	Closed	-$23.9M	–	191
2025 Q3	$23.9M	Buy	354,452 +3,151	+0.9%	+$249K	1.16%	32
2025 Q2	$30.7M	Buy	351,301 +13,699	+4%	+$1.07M	1.53%	22
2025 Q1	$23.1M	Buy	337,602 +24,405	+8%	+$1.99M	1.23%	29
2024 Q4	$24.4M	Buy	313,197 +4,364	+1%	+$323K	1.28%	26
2024 Q3	$20.7M	Buy	308,833 +36,192	+13%	+$2.97M	1.05%	34
2024 Q2	$30.9M	Buy	272,641 +10,892	+4%	+$1.38M	1.65%	21
2024 Q1	$36.3M	Buy	261,749 +3,472	+1%	+$436K	1.86%	17
2023 Q4	$32M	Buy	258,277 +31,580	+14%	+$3.23M	1.77%	21
2023 Q3	$21.2M	Buy	+226,697	New	+$25.6M	1.27%	31

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JSC

J. Stern & Co London, United Kingdom $1.03B AUM 20.71% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Waters Parkerson & Co's DXCM Position: Q4 2025 in Review

Waters Parkerson & Co sold out of DexCom (DXCM) in Q4 2025, closing a stake of 354,452 shares — an estimated $23.9M sold.

Waters Parkerson & Co first reported a position in DXCM in Q3 2023 and held it in 9 quarters. The position peaked at $36.3M in Q1 2024. 921 funds tracked by Wall St. Rank hold DXCM as of Q4 2025.

Waters Parkerson & Co reported no remaining DexCom position as of Q4 2025 after selling out during the quarter.
Waters Parkerson & Co sold 354,452 DexCom shares in Q4 2025, an estimated $23.9M.
Waters Parkerson & Co first reported a position in DexCom in Q3 2023 and held it in 9 quarters.
Waters Parkerson & Co's DexCom position peaked at $36.3M in Q1 2024.
921 funds tracked by Wall St. Rank held DexCom as of Q4 2025.

Based on Waters Parkerson & Co's 13F filing for Q4 2025, filed 12 Feb 2026.